<DOC>
	<DOCNO>NCT01575561</DOCNO>
	<brief_summary>This open-label , multi-center,12 week extension study design evaluate longer term safety , tolerability effectiveness lurasidone , flexibly dose , adjunctive lithium divalproex treatment subject bipolar I disorder , either complete core study D1050296 experience protocol define recurrence mood event double-blind phase core study D1050296</brief_summary>
	<brief_title>This Open-label , Multi-center , Extension Study Designed Evaluate Longer Term Safety , Tolerability Effectiveness Lurasidone , Flexibly Dosed , Adjunctive Lithium Divalproex Treatment Subjects With Bipolar I Disorder Who Have Participated Study D1050296</brief_title>
	<detailed_description>To evaluate long term safety lurasidone ( 20 , 40 , 60 80 mg/day ) subject bipolar I disorder . Subjects initially treat open-label lurasidone 40 mg/day ( Day 1 ) . Dose adjustment study drug ( 20 , 40 , 60 80 mg /day ) occur regularly schedule visit increments/decrements 1 dose level .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<criteria>Subject agree participate providing write informed consent . Subject complete 28 week Doubleblind Phase Study D1050296 require assessment final study visit ( Week 28 , Visit 28 ) ; OR Subject experience protocoldefined recurrence mood event Double blind Phase Study D1050296 complete required assessment final study visit ; OR Subject least entered Openlabel Phase Study D1050296 Sponsor stop study complete required assessment final study visit . Subject judge Investigator suitable participation 12 week clinical trial involve openlabel lurasidone treatment able comply protocol opinion Investigator . Subject consider Investigator imminent risk suicide injury self , others , property . Subject answer `` yes '' `` Suicidal Ideation '' item 4 ( active suicidal ideation intent act , without specific plan ) item 5 ( active suicidal ideation specific plan intent ) Columbia Suicide Severity Rating Scale ( CSSRS ) extension baseline visit ( final study visit Study D1050296 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Lurasidone</keyword>
	<keyword>Latuda</keyword>
	<keyword>Bipolar Disorder</keyword>
</DOC>